TABLE 2.
Association of participant demographics and clinical characteristics by microRNA-155 positivity status (n = 80).
| Variables | Total (%) | Negative microRNA155 n (%) a | Positive microRNA155 n (%) | P-value b |
|---|---|---|---|---|
| Total sample | 80 | 60 (75.0) | 20 (25.0) | |
| Gender Female Male |
36 (45.0) 44 (55.0) |
28 (77.8) 32 (72.7) |
8 (22.2) 12 (27.3) |
0.004 |
| Age group (years) (mean ± SD) 8–12 13–17 |
13.19 ± 2.51 32 (40.0) 48 (60.0) |
13.27 ± 2.43 23(71.9) 37 (77.1) |
13.00 ± 2.71 9 (28.1) 11 (22.9) |
0.598 |
| Residency Rural Urban |
47 (58.8) 33 (41.3) |
35 (74.5) 25 (75.8) |
12 (25.5) 8 (24.2) |
0.896 |
| EVBIgM Negative Positive |
41 (51.2) 39 (48.8) |
41 (100.0) 19 (48.7) |
0 (0.0) 20 (51.3) |
<0.001 |
| EVBIgG Negative Positive |
66 (82.5) 14 (17.5) |
51 (77.3) 9 (64.3) |
15 (22.7) 5 (35.7) |
0.308 |
| Interleukin-18 Negative Positive |
67 (83.8) 13 (16.3) |
55 (82.1) 5 (38.5) |
12 (17.9) 8 (61.5) |
0.001 |
| Interleukin-32 Negative Positive |
41 (51.2) 39 (48.8) |
40 (97.6) 20 (51.3) |
1 (2.4) 19 (48.7) |
<0.001 |
a
Frequency (%).
b
Chi-Square Tests.